Skip to main content
Premium Trial:

Request an Annual Quote

Abbott Posts 1 Percent Gain for MDx Sales in Q1

NEW YORK (GenomeWeb News) – Abbott reported this morning that its first-quarter molecular diagnostics sales increased around 1 percent year over year, while its overall diagnostics revenues climbed a little more than 4 percent.

The pharmaceuticals, diagnostics, and medical devices firm had total revenues of $5.38 billion, up 2 percent from $5.28 billion for the first quarter of 2012. Sales for its diagnostics business, overall, were $1.09 billion.

Molecular diagnostics sales were $106 million, up slightly from $105 million for the first quarter of 2012. Abbott reported US MDx sales of $48 million and international MDx sales of $58 million, which included an unfavorable 1 percent effect of foreign exchange.

MDx sales "were driven by strong growth in emerging markets, partially offset by market conditions in Europe," Abbott said in a statement. "We expect stronger performance beginning in the second quarter driven by positive impact from new tenders, infectious disease growth, and expansion in emerging markets."

Abbott's net income for the quarter dropped to $544 million, or $.34 per share, from $1.24 billion, or $.78 per share, for Q1 2012. Last year's results include $891 million from discontinued operations. At the beginning of this year, Abbott completed the separation of its research-based pharmaceutical business, which has been spun out into a publicly traded entity called AbbVie.

On an adjusted basis, Abbott's net earnings from continuing operations were $674 million, or $.42 per share, versus $645 million, or $.40 per share, for Q1 2012. It beat Wall Street's consensus estimate by a penny.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.